DMRA
$24.01
Post-MarketAs of Mar 17, 8:00 PM UTC
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$24.01
Potential Upside
5%
Whystock Fair Value$25.21
Price
UndervaluedFair ValueOvervalued
Fundamentals
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-109.49%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.28
Recent News
No recent news found.